Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRADUATE: Grazax and Dupilumab for Seasonal Allergic Rhinitis
NCT04502966Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2020
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dupilumab in seasonal allergic rhinitis (SAR), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT04502966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502966.